Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.

Literature DB >> 19199879

Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.

Robert E Becker¹, Latha K Unni, Nigel H Greig.

Abstract

Commercial priorities have been identified as negative factors in drug development. We trace the problem to inattention to sound clinical pharmacology practices. When properly applied, clinical pharmacology and associated drug development sciences can, hand in hand, facilitate success in commercial drug development.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19199879 PMCID： PMC5172379 DOI： 10.2174/156720509787313916

Source DB: PubMed Journal: Curr Alzheimer Res ISSN： 1567-2050 Impact factor: 3.498

14 in total

Review 1. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors: Robert E Becker; Nigel H Greig
Journal: Curr Alzheimer Res Date: 2008-08 Impact factor: 3.498

2. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.

Authors: R E Becker; J A Colliver; S J Markwell; P L Moriearty; L K Unni; S Vicari
Journal: Alzheimer Dis Assoc Disord Date: 1996 Impact factor: 2.703

Review 3. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Authors: Nigel H Greig; Kumar Sambamurti; Qian-sheng Yu; Arnold Brossi; Gosse B Bruinsma; Debomoy K Lahiri
Journal: Curr Alzheimer Res Date: 2005-07 Impact factor: 3.498

4. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

Authors: R E Becker; J A Colliver; S J Markwell; P L Moriearty; L K Unni; S Vicari
Journal: Alzheimer Dis Assoc Disord Date: 1998-03 Impact factor: 2.703

Review 5. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors: Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal: J Alzheimers Dis Date: 2008-10 Impact factor: 4.472

6. Recovery of acetylcholinesterase at intact neuromuscular junctions after in vivo inactivation with di-isopropylfluorophosphate.

Authors: H Kasprzak; M M Salpeter
Journal: J Neurosci Date: 1985-04 Impact factor: 6.167

Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.

Review 1. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

2. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.

Review 3. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

4. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

Review 5. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

6. Recovery of acetylcholinesterase at intact neuromuscular junctions after in vivo inactivation with di-isopropylfluorophosphate.

7. Rat brain acetylcholinesterase turnover in vivo: use of a radioactive methylphosphonothiate irreversible inhibitor.

8. Intra- versus extracellular recovery of 16S acetylcholinesterase following organophosphate inactivation in the rat.

9. The perils of Alzheimer's drug development.

10. Regulated and constitutive secretion of distinct molecular forms of acetylcholinesterase from PC12 cells.

1. Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?

Review 2. Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Review 3. Lost in translation: neuropsychiatric drug development.

4. Advances in Alzheimer therapy: understanding pharmacological approaches to the disease.

Review 5. A new regulatory road-map for Alzheimer's disease drug development.

Review 6. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.